The clinical study at the Reproductive Medicine Center (RMC) in Malmö is progressing well, with 68 couples successfully recruited to date and JUNO binding analysis completed in 51 cases. The Company remains on track to achieve its clinical objectives and is confident it will complete the study by the end of 2025, or potentially earlier. Interim results to date continue to demonstrate a correlation between JUNO binding and fertilization outcomes, with the next interim analysis expected this summer. These findings further support the potential of JUNO-Checked as a diagnostic tool in assisted reproductive treatments.

In parallel, Spermosens is in active dialogue with potential commercial partners in Europe, the US and Japan, who are closely following the clinical study. The Company has further strengthened its US business development through the collaboration with ScanMed Partners and expanded its European activities through the partnership with Scalania AG. In Japan, Spermosens continues a positive dialogue with an established company following the signing of a memorandum of understanding in late 2024, aiming to conclude a license agreement for the Japanese market based on positive outcome from the ongoing clinical study.

As previously communicated, Spermosens recently secured a strategic investment from European and US investors, providing the financial foundation necessary to execute on its strategy. This includes completing the ongoing clinical study, advancing the JUNO-Checked technology and continuing the pursuit of commercial partnerships.

Tore Duvold, CEO of Spermosens, comments: "We are encouraged by the strong recruitment rate in our clinical study, which continues to generate valuable data supporting our technology. We are confident in our ability to achieve our clinical goals and look forward to sharing the next set of interim results this summer. I am pleased to see our commercial discussions progressing, and we remain optimistic about securing strategic partnerships to support our commercialization efforts. With the financial backing we have secured, we are well-positioned to reach the next key milestones in the coming months."

Spermosens will continue to provide updates as the clinical study progresses and commercial discussions advance.

For further information, please contact:
Tore Duvold, CEO
E-mail: info@spermosens.com

Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com